Microarray analysis of gene expression in liver, adipose tissue and skeletal muscle in response to chronic dietary administration of NDGA to high-fructose fed dyslipidemic rats

Haiyan Zhang1,2,3, Wen-Jun Shen1,2, Yihang Li1,2,4, Alex Bittner1, Stefanie Bittner1, Juveria Tabassum1, Yuan F. Cortez1, Fredric B. Kraemer1,2 and Salman Azhar1,2*

Abstract

Nordihydroguaiaretic acid (NDGA), the main metabolite of Creosote Bush, has been shown to have profound effects on the core components of metabolic syndrome, including lowering of blood glucose, free fatty acids and triglyceride levels, attenuating elevated blood pressure in several rodent models of dyslipidemia, and improving body weight, insulin resistance, diabetes and hypertension. In the present study, a high-fructose diet fed rat model of hypertriglyceridemia, dyslipidemia, insulin resistance and hepatic steatosis was employed to investigate the global transcriptional changes in the lipid metabolizing pathways in three insulin sensitive tissues: liver, skeletal muscle and adipose tissue in response to chronic dietary administration of NDGA. Sprague-Dawley male rats (SD) were fed a chow (control) diet, high-fructose diet (HFrD) or HFrD supplemented with NDGA (2.5 g/kg diet) for eight weeks. Dietary administration of NDGA decreased plasma levels of TG, glucose, and insulin, and attenuated hepatic TG accumulation. DNA microarray expression profiling indicated that dietary administration of NDGA upregulated the expression of certain genes involved in fatty acid oxidation and their transcription regulator, PPARα, decreased the expression of a number of lipogenic genes and relevant transcription factors, and differentially impacted the genes of fatty acid transporters, acetyl CoA synthetases, elongases, fatty acid desaturases and lipid clearance proteins in liver, skeletal muscle and adipose tissues. These findings suggest that NDGA ameliorates hypertriglyceridemia and steatosis primarily by inhibiting lipogenesis and enhancing fatty acid catabolism in three major insulin responsive tissues by altering the expression of key enzyme genes and transcription factors involved in de novo lipogenesis and fatty acid oxidation.

Keywords: Fatty acid oxidation, Lipogenesis, Steatosis, Hypertriglyceridemia, CD36, L-FABP, Malony-CoA decarboxylase

Background

Nonalcoholic fatty liver disease (NAFLD), the most common cause of chronic liver disease [1–3], is a major health problem worldwide [2, 4]. NAFLD encompasses a spectrum of disease ranging from simple steatosis (excessive accumulation of fat mainly in the form of triglycerides [5–7]), nonalcoholic steatohepatitis (NASH) that includes steatosis along with inflammation and fibrosis and end-stage disease, cirrhosis and liver failure [8, 9] and a subsequent potential for hepatocellular carcinoma [10]. During the past few decades, the prevalence and severity of NAFLD have been paralleled with that of obesity, type 2 diabetes and metabolic syndrome (MetS) [4, 11, 12] and many studies have reported a pathophysiologic association between NAFLD and these disorders [11–18]. MetS is the umbrella description given to a number of derangements including insulin resistance and glucose intolerance,
(central) obesity, dyslipidemia, and hypertension [19–21]. NAFLD is closely tied to insulin resistance and hepatic dyslipidemia and is now considered as a hepatic manifestation of MetS [12, 14–17]. The current evidence indicates NAFLD is an independent risk factor for the development of type 2 diabetes [13, 17, 18] and cardiovascular disease [12, 22–24]. Currently, there are no designated therapies in the clinical management of NAFLD except lifestyle modification including weight reduction, diet and exercise, which are hard to comply with on a long-term schedule [25–27].

Although the exact cause of the rising prevalence of NAFLD is not fully understood, the rapid urbanization, over-nutrition (consumption of high-carbohydrate and high-fat calorie-rich diets), increasing consumption of sugar sweetened (such as sucrose [cane or beet sugar] and high-fructose corn syrup [HFCS]) caloric beverages (i.e., soft-drinks and colas) and increasingly sedentary lifestyles, all have been linked with the increasing incidence of this disease [28–33]. In recent years, considerable attention has been paid to the contribution of dietary carbohydrates, sugar-sweetened beverages and monosaccharide fructose, in particular, in the pathogenesis of NAFLD [28, 30, 32, 34, 35]. The role of fructose in NAFLD (steatosis) pathogenesis has received a great deal of attention in part because from 1999 to 2004 the consumption of fructose increased by ~32 % [36]. HFCS now represents nearly 50 % of caloric sweeteners used in the United States [37]. Hepatic fructose metabolism differs from glucose [35, 38], and, in a hypercaloric setting, fructose induces hypertriglyceridemia and visceral adiposity, promotes lipogenesis and ectopic lipid accumulation, and decreases insulin sensitivity in humans [30, 32, 39–44] as well as rodents [30, 38, 45–52]. Based on these various findings, it appears that excessive consumption of fructose contributes to NAFLD pathogenesis in two ways: 1) it promotes TG production via de novo lipogenesis resulting in hyperlipidemia; and 2) it contributes to inflammation resulting in insulin resistance, steatosis, hepatic inflammation and fibrosis [53].

The creosote bush – Larrea tridentate – which grows abundantly in the North American and Mexican deserts, has been used by tribes native to these areas in the treatment of a wide range of ailments, including kidney and gallbladder stones, infertility, chicken pox, tuberculosis, cancer, venereal disease, colds, pain, arthritis and inflammation [54]. Previous work from our laboratory ([55, 56] and references therein) and others [57, 58] has shown that nordihydroguaiaretic acid (NDGA), the main metabolite of Creosote Bush [54], has profound effects on the core components of metabolic syndrome, including lowering of blood glucose, free fatty acids (FFA) and triglyceride (TG) levels, and attenuating elevated blood pressure in several rodent models of dyslipidemia, as well as improving body weight (obesity), insulin resistance, diabetes and hypertension. In a recently published study [59] we provided evidence using control, high-fat diet fed C57BL/6 J pre-diabetes (diet-induced obesity [DIO]), ob/ob control and NDGA fed DIO and ob/ob mice that NDGA exerts its hypolipidemic actions, including amelioration of hepatic steatosis, predominantly by stimulating the activity of the nuclear hormone receptor, peroxisome proliferator activated α (PPARα or NR1C1), the master regulator of all three hepatic fatty acid oxidation systems [60–67], which, in turn, improves dyslipidemia by promoting increased channeling of fatty acids towards their oxidation, and thus, restricting very low-density lipoprotein (VLDL)-TG production, storage, and secretion. We additionally observed that PPARα-independent pathways might also contribute to NDGA’s action to ameliorate hepatic steatosis.

To gain further insight into the molecular mechanisms underlying NDGA attenuation of dyslipidemia, including hypertriglyceridemia and hepatic steatosis, we utilized a microarray approach, which allowed us to observe the global effect of NDGA on lipid metabolism in three insulin sensitive tissues, liver, skeletal muscle and adipose tissues from high-fructose diet (HFrD)-induced hyperinsulinemic, hyperinsulinemic and hypertriglyceridemic rats. More specifically, the major goal of this study was to examine the effects of NDGA on expression of genes involved in lipid metabolism using HFrD fed rats to identify expression changes that might explain metabolic (i.e., insulin resistance, steatosis and hypertriglyceridemia) and histological (i.e., lipid droplet density) that are observed with NDGA treatment. Our results indicate that NDGA affects the expression of a large number of genes involved in fatty acid catabolism and synthesis in liver, muscle, and adipose tissue. In addition, based on these two affected pathways, several genes have been identified that may mediate the anti-hyperlipidemic actions of NDGA.

**Results**

**Effect of chronic dietary NDGA treatment on physical and metabolic characteristics of high-fructose diet fed rats**

We examined the effects of chronic dietary NDGA treatment on hypertriglyceridemia and hepatic steatosis, and profiled by microarray analysis the expression of enzymes and regulatory proteins involved in lipid metabolism of three insulin-sensitive tissues liver, skeletal muscle and adipose tissue. For these studies, the groups of rats were maintained on a control Chow diet, HFrD or HFrD supplemented with 2.5 g NDGA/kg diet (HFrD-NDGA) (~94 mg/kg BW/24 h) for 16 weeks and, subsequently, liver, mixed gastrocnemius muscle and white adipose tissue samples were subjected to Gene Microarray Analysis. Serum samples collected at various time
points were quantified for triglyceride, cholesterol, glucose and insulin levels. Chronic feeding of HFrD to male rats leads to hypertension, hyperinsulinemia, hypertriglyceridemia and inflammation [47, 56, 68].

There was no obvious gastrointestinal stress as manifest by diarrhea observed during the dietary treatment. Compared to the chow-fed control group, there was a significant reduction of body weight starting after 1 week in both HFrD and HFrD-NDGA groups (Fig. 1[a]). Furthermore, dietary consumption of NDGA resulted in much lower body weights as compared to either the HFrD or chow diet. There was no significant difference in food intake between the groups (Fig. 1[b]). These results suggest that suppression of body weight gain in HFrD-NDGA supplementation in the diet is not due to changes in food intake, but most likely due to increased energy expenditure and decreased adiposity. HFrD-induced increases in serum triglyceride levels were completely prevented in rats maintained on HFrD supplemented with NDGA (Fig. 2[a]). However, total cholesterol (Fig. 2[b]) and glucose were not different among the three groups except at weeks 9, 11 and 16. At week 9, total cholesterol levels were significantly higher following NDGA treatment ($P < 0.01$ Chow vs HFrD-NDGA; $P < 0.05$ HFrD vs HFrD-NDGA), whereas at 11 and 16 weeks, glucose levels were reduced in response to feeding HFrD ($P < 0.05$ Chow vs HFrD) and HFrD-NDGA ($P < 0.05$ Chow vs HFrD-NDGA), respectively (Fig. 2[b, c]). As shown in Fig. 2[d], circulating insulin levels were markedly increased with HFrD feeding, but decreased to almost control levels, although were significantly different than chow with the dietary administration of NDGA ($P < 0.001$).

**Effect of chronic dietary NDGA treatment on hepatic lipid accumulation**

Liver weights were significantly higher in both HFrD and HFrD-NDGA groups than controls, but no differences were noted between HFrD and HFrD-NDGA groups (Fig. 3[a]). Liver TG content increased approximately 6-fold in animals fed HFrD compared with control rats ($P < 0.001$) and decreased by approximately 70% in response to HFrD-NDGA feeding ($P < 0.001$) (Fig. 3[b]). We also performed histological examinations on H&E stained liver sections prepared from chow, HFrD and HFrD-NDGA groups to assess the extent of hepatic steatosis. Hepatocytes from HFrD fed rats contained more lipids (white space) than control rats (Fig. 3[c]). In comparison, the extent of steatosis in liver tissue of rats fed HFrD-NDGA was reduced to the levels seen in chow-fed animals (Fig. 3[c]). We also calculated liver/body weight ratios. As can be seen in Fig. 4, HFrD + NDGA/body weight ratio was higher than HFrD/Body weight ratio. We speculate that this occurs because of increased hepatic glycogen accumulation, since livers of NDGA treated animals preferentially use fatty acids as an energy source. Similar results have been reported by Lee et al. [57] showing that high-fat diet (HFD) mice treated with NDGA had a higher liver body weight ratio than mice fed HFD alone.

**Principal component analysis of microarrays**

Initially a principal component analysis (PCA) was performed to visualize patterns in the gene expression data and to highlight similarities and differences between the two diets (Chow vs HFrD) and NDGA treatment (HFrD vs HFrD-NDGA). Data are displayed in a simple Scatter Plot view of the first two principal components (PCs).
Fig. 2 Effects of dietary administration of NDGA on plasma metabolites. a triglyceride, b total cholesterol, c glucose, and d insulin. Rats were fed a chow diet, HFrD or HFrD-NDGA (2.5 g/kg diet) for 8 weeks. Results are means ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001 vs Chow, † p < 0.05, †† p < 0.01, ††† p < 0.001 vs HFrD.

Fig. 3 Effects of dietary administration of NDGA on liver weight, liver TG content and liver histology. a liver weight, b liver TG content, and c liver histology. Rats were fed a chow diet, HFrD or HFrD-NDGA (2.5 g/kg diet) for 8 weeks. Results are means ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001 vs Chow, † p < 0.05, †† p < 0.01, ††† p < 0.001 vs HFrD.
of a number of lipogenic genes, including Gckr, Gck, Pkr, Acly, Fasn, Scd1, Fads1, Fads2, Elov12, Elov15, and Elov16.

The expression of acyl-CoA synthetases, which channel fatty acids into different pathways of lipid metabolism, was differentially impacted by NDGA treatment; NDGA treatment increased Acs1l and Acs3 mRNA levels, but decreased Acs4 and Acs2 levels (Table 1). Likewise, NDGA treatment differentially increased Abcc3, Abcc5, Lpl, and Vldr and decreased Abcc6, Apoa4, Apof, genes that participate in lipid clearance. Surprisingly, NDGA showed no significant effect on various genes involved in TG synthesis/asemblly with the exception of Mogat1 (↑), Dgat2 (↓) and Arf3 (↓). Key transcription factors of hepatic lipid metabolism, such as Hnf4a, Ppara, Nr1h3 and Ppargc1b, showed enhanced expression, whereas Foxa1, Mixipl, Srebf1, Ppard and Xbp1 expression was significantly reduced in HFrD-NDGA treated animals as compared to HFrD treated animals (Table 1).

Qualitatively similar to hepatic gene expression, data were obtained for the mixed gastrocnemius muscle, a representative of skeletal muscle types. Expression of fatty acid oxidation genes, Cpt1c, Acox1, Acdsb, Dei, and Ehhadh, was up-regulated, but the expression of Cpt1a, Cpt1b and Peci was down-regulated with NDGA treatment (Table 2). Four fatty acid synthesizing enzyme genes (Gckr, Gck, Fads1 and Fads2) were upregulated by NDGA treatment, but the expression of three genes, (Acly, Elov11 and Elov15) was down-regulated in response to NDGA treatment. No NDGA effect was noted on the expression levels of key lipogenic enzymes, Fasn and Scd1. The expression levels of fatty acid transport proteins Slc27a1 and Slc27a1 and acyl-CoA synthetases Acs2 and Acs1 were up-regulated and down-regulated, respectively, as a result of NDGA treatment. The key TG synthesizing genes Agpat1, Dgat1 and Dgat2 were increased in the HFrD-NDGA treated group compared to HFrD alone, but the expression levels of other genes, Agpat2, Mogat1 and Arf3, were reduced with NDGA treatment. The expression levels of some genes involved in lipid clearance, Abcc4, Abcc11, Apob, Apoc2, Apoc3 and Vldlr, were significantly upregulated, while levels of Abcc3, Apoe and Lpl were downregulated in response to NDGA treatment of HFrD fed rats. Interestingly, NDGA treatment increased the expression of both transcription factors involved in fatty acid oxidation (Ppara and Ppargc1) and fatty acid synthesis (Nr1h3, Srebf1 and Xbp1) (Table 2).

Comparison of liver and skeletal muscle, relatively less effect of NDGA was detected on lipid metabolizing genes in white adipose tissue (Table 3). The adipose expression of fatty acid transporter Slc27a1 was significantly reduced by high-fructose feeding, whereas its
levels were markedly increased in HFrD rats treated with NDGA. Likewise, consumption of the high-fructose diet led to down-regulation of the majority of fatty acid oxidation genes except Acox1, whereas NDGA treatment increased expression of only Acdsb and Acadvl (Table 3). In addition, HFrD feeding increased the expression of lipogenic genes such as Gck, Pklr, Acly, and Scd1, but reduced the levels of Elovl1. Simultaneous HFrD and NDGA feeding decreased the expression of several lipogenic genes, e.g., Gck, Pklr, Scd1, and Fads1, but increased the expression Elovl1, Elovl5 and Elovl6. The expression of a number of genes involved in TG synthesis, such as Agpat1, Agpat3, Agpat6, Agpat9, Dgat1 and Arf3, were reciprocally regulated by HFrD feeding and HFrD-NDGA treatment. Both high-fructose feeding and combined high-fructose diet and NDGA treatment markedly altered the expression of key genes involved in lipid clearance, e.g., Apo4, Apoc2, Apoc3, Apoe, VLDLR and Lpl (Table 3). Among the lipid transcription factors, the expression of Ppara, Srebf1, and Nr1h3 was increased following NDGA treatment, whereas high-fructose feeding alone decreased the expression of Ppargc1b and Srebf1 genes. In contrast, HFrD feeding increased the expression of Pparg1a.

Discussion
The objective of this study was to examine the effects of dietary administration of NDGA on gene expression involved in lipid homeostasis in liver, skeletal muscle and adipose tissue in rats chronically fed a 60 % fructose diet. A secondary goal was to utilize the information about the expression patterns of genes to identify lipid genes and pathways and modulators of lipid metabolism that might be the targets of NDGA amelioration of hypertriglyceridemia and hepatic steatosis. We examined gene expression in liver, gastrocnemius muscle (a representative of skeletal muscle) and white adipose tissue when rats were fed a chow, or HFrD supplemented with ± NDGA. We selected liver, skeletal muscle and adipose tissue for the following reasons: 1) the liver is a major organ responsible for fatty acid catabolism, de novo lipid synthesis (lipogenesis), triglyceride synthesis and export in the form of VLDL-TG; 2) skeletal muscle is a major site of fatty acid oxidation; and 3) fat stored as triglyceride in adipose tissue and mobilized in the form of plasma free fatty acids (FFAs) is the major fuel reserve and fuel source. In addition, all three tissues are highly sensitive to insulin action. We identified a number of genes involved in fatty acid oxidation, lipogenesis, and
| Gene symbol/GenBank accession/ Gene ID | Entrez gene name | HFrD/Chow (Fold-change) | HFrD-NDGA/HFrD (Fold-change) |
|--------------------------------------|-----------------|-------------------------|-----------------------------|
| **Fatty Acid Transport**              |                 |                         |                             |
| Slc27a1                              | Soluble carrier family 27 (fatty acid transporter), member 1 (FATP1) | 0.817382 (p = 0.050249)    | 1.085686 (p = 0.548792)     |
| Slc27a2                              | Soluble carrier family 27 (fatty acid transporter), member 2 (FATP2) | 1.276261† (p = 0.017602)   | 1.071673 (p = 0.458057)     |
| **Acyl-CoA Synthetases**              |                 |                         |                             |
| Acsl1                                | Acyl-CoA synthetase long-chain family member 1 (ACS, Acas, COAA, Fac1) | 1.058003 (p = 0.59888)     | 1.286236† (p = 0.015343)    |
| Acsl4                                | Acyl-CoA synthetase long-chain family member 4 (ACSA4, Fac4) | 1.673512† (p = 0.000004)   | 0.697139↓ (p = 0.001224)    |
| Acsm3                                | Acyl-CoA synthetase medium-chain family member 3 (Sa, Sah) | 0.458851↓ (p = 0.000004)   | 1.583156† (p = 0.000039)    |
| Acss2                                | Acyl-CoA synthetase short chain family member 2 (Accs2) | 1.640823† (p = 5.92E-09)   | 0.707869↓ (p = 0.000022)    |
| **Fatty Acid Oxidation**              |                 |                         |                             |
| Cpt1a                                | Carnitine palmitoyltransferase 1a, liver (CPT-1a) | 2.093217† (p = 0.000002)   | 0.935127 (p = 0.569094)     |
| Cpt1b                                | Carnitine palmitoyltransferase 1b, muscle (CPT-1B, M-CPT1) | 0.955041 (p = 0.714963)    | 4.901597↑ (p = 1.32E-23)    |
| Cpt1c                                | Carnitine palmitoyltransferase 1c (CPT 1C, CPT1-B, CPT1-B) | 0.786901 (p = 0.063481)    | 0.809912 (p = 0.13046)      |
| Cpt2                                 | Carnitine palmitoyltransferase 2 (CPTII) | 1.119695 (p = 0.344743)    | 2.583082↑ (p = 1.88E-16)    |
| Acox1                                | Acyl-CoA oxidase, palmitoyl (Rat ACOA1) | 1.165664 (p = 0.176539)    | 3.27028† (p = 5.20E-32)     |
| Acox2                                | Acyl-CoA oxidase, palmitoyl (Rat ACOA1) | 1.165664 (p = 0.176539)    | 3.27028† (p = 5.20E-32)     |
| Acox3                                | Acyl-CoA dehydrogenase, long chain (ACOADA, LCAD) | 1.156082 (p = 0.178078)    | 1.023617 (p = 0.843391)     |
| Acoa1                                | Acyl-CoA dehydrogenase, C-4 to C-12 straight chain (MCAD) | 0.871033 (p = 0.206145)    | 1.171654 (p = 0.099023)     |
| Acoa2                                | Acyl-CoA dehydrogenase, C-2 to C-3 short chain (Scad) | 1.125432 (p = 0.554859)    | 0.919627 (p = 0.563538)     |
| Acoa3                                | Acyl-CoA dehydrogenase, short/branched chain | 1.060392 (p = 0.654381)    | 0.700742↓ (p = 0.030057)    |
| Acoa4                                | Acyl-CoA dehydrogenase very long chain (VLCAD) | 1.034174 (p = 0.763361)    | 1.322826† (p = 0.003236)    |
| Eci7                                 | Enoyl-CoA delta isomerase 1 (Deci) | 0.991668 (p = 0.91246)     | 2.461649† (p = 1.48E-11)    |
| Ech7                                 | Enoy-CoA hydratase, short chain 1, mitochondrial | 1.001718 (p = 0.984367)    | 0.982888 (p = 0.872986)     |
| Ehbadh                               | Enoy-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase | 1.159127 (p = 0.181858)    | 5.837078† (p = 2.67E-36)    |
| ID        | Gene                        | Description                                                                 | HFrD-NDGA     | HFrD             |
|-----------|------------------------------|----------------------------------------------------------------------------|---------------|------------------|
| 171142    | Eci2                         | Enoyl-CoA delta isomerase 2 (Peci)                                          | 1.109171      | 1.04819          |
|           |                              |                                                                              | (p = 0.294883) | (p = 0.563012)   |
| 291075    | Enoyl-CoA delta isomerase 2   | Fatty Acid Synthesis/ De Novo Lipogenesis                                    |               |                  |
| 1.109171  |                              |                                                                              | (p = 0.294883) | (p = 0.563012)   |
| 1.04819   |                              |                                                                              | (p = 0.294883) | (p = 0.563012)   |
| 25658     | Gckr                         | Glucokinase (hexokinase 4) regulator (GLRE)                                  | 1.225835†     | 0.842312‡        |
|           |                              |                                                                              | (p = 0.00735)  | (p = 0.029236)   |
| 24385     | Gck                          | Glukokinase (GLUKA, RNGK2)                                                  | 1.225835†     | 0.842312‡        |
|           |                              |                                                                              | (p = 0.00735)  | (p = 0.029236)   |
| 24651     | Pklr                         | Pyruvate kinase, liver and RBC (PK1, PKL, Pklg)                              | 2.101247†     | 0.763246         |
|           |                              |                                                                              | (p = 0.013312) | (p = 0.331269)   |
| 24159     | Acly                         | ATP citrate lyase (ACL, Clatp)                                               | 3.860112†     | 0.669940         |
|           |                              |                                                                              | (p = 8.66E-38) | (p = 0.000006)   |
| 50761     | Fasn                         | Fatty acid synthase                                                          | 8.556156†     | 0.448329         |
|           |                              |                                                                              | (p = 0.00E + 00)| (p = 2.08E-16)  |
| 24552     | Me1                          | Malic enzyme 1, NADP(+)−dependent, cytosolic (MOD1)                          | 8.437617†     | 1.132866         |
|           |                              |                                                                              | (p = 2.81E-20) | (p = 0.447740)   |
| 307270    | Me2                          | Malic enzyme 2, NAD(+)−dependent, mitochondrial                              | —             | —                |
| 246074    | Scd1                         | Stearyl-Coenzyme A desaturase 1                                             | 9.689369†     | 0.563616         |
|           |                              |                                                                              | (p = 1.82E-38) | (p = 3.64E-11)   |
| 67953.2   | Elovl1                       | ELLOVL fatty acid elongase 1                                                | 0.996626      | 0.956685         |
|           |                              |                                                                              | (p = 0.968014) | (p = 0.573719)   |
|           |                              |                                                                              | and           | (p = 0.664855)   |
|           |                              |                                                                              | 0.943940      | 1.033276         |
|           |                              |                                                                              | (p = 0.460163) | (p = 0.664855)   |
| 498728    | Elovl2                       | ELLOVL fatty acid elongase 2                                                | 2.461290†     | 0.498430         |
|           |                              |                                                                              | (p = 6.36E-19)| (p = 3.66E-11)   |
| 315851    | Elovl4                       | ELLOVL fatty acid elongase 4                                                | 0.823072      | 1.658203†        |
|           |                              |                                                                              | (p = 0.428065) | (p = 0.022936)   |
| 315851    | Elovl5                       | ELLOVL fatty acid elongase 5 (rELO1)                                        | 1.899944†     | 0.416035         |
|           |                              |                                                                              | (p = 1.23E-11)| (p = 1.73E-17)   |
| 171400    | Elovl6                       | ELLOVL fatty acid elongase 6 (Lce2, rELO2)                                  | 9.009938†     | 1.516733†        |
|           |                              |                                                                              | (p = 0.00E + 00)| (p = 6.34E-09)  |
|           |                              |                                                                              | and           | (p = 0.000012)   |
|           |                              |                                                                              | 2.808326†     | 1.466229†        |
|           |                              |                                                                              | (p = 5.04E-11)| (p = 0.000012)   |
| 84575.5   | Fads1                        | Fatty acid desaturase 1                                                     | 1.241893†     | 0.760081†        |
|           |                              |                                                                              | (p = 0.044164) | (p = 0.006978)   |
| 84575.5   | Fads2                        | Fatty acid desaturase 2 (Fadsd6)                                            | 2.161421†     | 0.699797†        |
|           |                              |                                                                              | (p = 8.64E-12)| (p = 0.000034)   |
| 85239     | Mlcyd                        | Malonyl-CoA decarboxylase                                                   | 1.018118      | 1.421141†        |
|           |                              |                                                                              | (p = 0.862908) | (p = 0.000017)   |
| Gene          | Description                                      | HFrD        | HFrD-NDGA   |
|--------------|--------------------------------------------------|-------------|-------------|
| **Triglyceride (TG) Synthesis/VLDL-TG Assembly** |
| Agpat1       | 1-Acylglycerol-3-phosphate O-acyltransferase 1   | 0.695809    | 0.906865    |
|              |                                                  | (p = 0.00083) | (p = 0.595394) |
| Agpat2       | 1-Acylglycerol-3-phosphate O-acyltransferase 2   | 0.846901    | 1.048686    |
|              |                                                  | (p = 0.109629) | (p = 0.622341) |
| Agpat3       | 1-Acylglycerol-3-phosphate O-acyltransferase 3   | 0.848841    | 0.895847    |
|              |                                                  | (p = 0.540663) | (p = 0.800248) |
| Agpat6       | 1-Acylglycerol-3-phosphate O-acyltransferase 6   | 1.024470    | 0.977072    |
|              | (RGD1310520)                                     | (p = 0.740343) | (p = 0.773786) |
| Agpat9       | 1-Acylglycerol-3-phosphate O-acyltransferase 9   | ---         | ---         |
| **Mogat1**   | Monoacylglycerol O-acyltransferase 1             | 0.682029    | 1.75896†    |
|              |                                                  | (p = 0.154868) | (p = 0.030197) |
| **Dgat1**    | Diacylglycerol O-acyltransferase 1 (ARAT, Dgat)  | 1.222808†   | 1.067215    |
|              |                                                  | (p = 0.030522) | (p = 0.775797) |
| **Dgat2**    | Diacylglycerol O-acyltransferase 2 (ARAT)        | 1.171782†   | 0.664628↓   |
|              |                                                  | (p = 0.67572) | (p = 0.000124) |
| **Arf3**     | ADP-ribosylation factor 3 (AC1-253)              | 1.046754    | 0.743228†   |
|              | Cholesterol Synthesis/Metabolism                 |             | (p = 0.575272) | (p = 0.001530) |
| Acat2        | Acetyl-CoA acetyltransferase 2 (Acat3, Ab2-076)  | 0.944516    | 0.957373    |
|              |                                                  | (p = 0.461984) | (p = 0.56688) |
| Hmgcr        | 3-Hydroxy-3-methylglutaryl-CoA reductase (3H3M)  | 1.438208†   | 0.735862†   |
|              |                                                  | (p = 0.000036) | (p = 0.002383) |
| **Insig 1**  | Insulin induced gene 1                           | 2.844270†   | 0.542157†   |
|              |                                                  | (p = 9.18E-16) | (p = 0.000001) |
| **Insig 2**  | Insulin induced gene 2                           | 0.831160↓   | 0.630641↓   |
|              |                                                  | (p = 0.044277) | (p = 8.36E-09) |
| Ldr          | Low density lipoprotein receptor (LDLRA)         | 1.439569†   | 0.840219    |
|              |                                                  | (p = 0.003984) | (p = 0.137488) |
| Mvk          | Mevalonate kinase (Lrbp)                         | 0.663626↓   | 1.149403    |
|              |                                                  | (p = 0.000016) | (p = 0.234165) |
| Scap         | SREBF chaperone Proteins Involved in Lipid Clearance | 1.171144†   | 0.995421    |
|              |                                                  | (p = 0.035192) | (p = 0.941247) |
| **Abca4**    | ATP-binding cassette, subfamily A (ABC1), member 4 (ABCR) | ---         | ---         |
| **Abcb4**    | ATP-binding cassette, subfamily B (MDR/TAP), member 4 (Mdr2, Pgy3) | 0.489385↓   | 1.099759    |
|              |                                                  | (p = 3.69E-12) | (p = 0.27820) |
| **Abcb1f**   | ATP-binding cassette, subfamily B (MDR/TAP), member 11 (Bsep, Spgp) | 0.752953↓   | 1.158787    |
|              |                                                  | (p = 0.001332) | (p = 0.07294) |
Table 1 Hepatic genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA) (Continued)

| Gene | Acc: | ID | Description | HFrD | HFrD-NDGA |
|------|------|----|-------------|------|-----------|
| Abcc3 | NM_080581.1 | 140668 | ATP-binding cassette, subfamily C (CFTR/MRP), member 3 (Mlp2, Mrp3) | 0.813337 | (p = 0.08045) | 2.659410† | (p = 7.16E-11) |
| Abcc6 | NM_031013.1 | 81642 | ATP-binding cassette, subfamily C (CFTR/MRP), member 6 (Mrp6) | 1.085723 | (p = 0.31384) | 0.717441↑ | (p = 0.00001) |
| Abcd1 | NM_001108821.1 | 363516 | ATP-binding cassette, subfamily D (ALD), member 3 (RGD1562128) | 1.085723 | (p = 0.468224) | 0.943107 | (p = 0.56163) |
| Abcd3 | NM_012804.1 | 25270 | ATP-binding cassette, subfamily D (ALD), member 3 (PMP70, Pxmp1) | 1.178867 | (p = 0.035741) | 2.15542↑ | (p = 2.62E-16) |
| Abcg2 | NM_181381.2 | 312382 | ATP-binding cassette, subfamily G (WHITE), member 2 (BCRP1) | 1.940981 | (p = 0.00000) | 1.140117 | (p = 0.258891) |
| Abcg5 | NM_053754.2 | 114628 | Apolipoprotein A-IV (Apo-AIV, ApoA-IV, ApoAIV) | 1.316723 | (p = 0.025675) | 0.447885↓ | (p = 1.8E-10) |
| ApoA | NM_019287.2 | 54225 | Apolipoprotein B (Aa1064, AC1-060, Apo B-100, ApoB-100, ApoB-48) | 0.895361 | (p = 0.277000) | 1.130493 | (p = 0.142599) |
| ApoE | NM_012737.1 | 25080 | Apolipoprotein C-II (RGD1560725) | 0.981675 | (p = 0.864333) | 0.941418 | (p = 0.591544) |
| ApoF | NM_012804.1 | 25270 | Apolipoprotein C-III (ApoC-III, apo-CIII) | 0.887282 | (p = 0.221273) | 1.133806 | (p = 0.221176) |
| ApoE | NM_138828.2 | 25728 | Apolipoprotein E (APOEA) | 0.953286 | (p = 0.543392) | 0.968783 | (p = 0.80654) |
| ApoF | NM_001024351.1 | 500761 | Apolipoprotein F | 1.053397 | (p = 0.630710) | 0.558207↓ | (p = 0.000001) |
| Lpl | NM_012498.2 | 24539 | Lipoprotein lipase | 1.300129↑ | (p = 0.024577) | 3.799195↑ | (p = 1.34E-16) |
| VldR | NM_013155.2 | 25696 | Very low density lipoprotein receptor | 0.993145 | (p = 0.373839) | 1.615341↑ | (p = 0.012976) |
| Ppt1 | NM_022502.2 | 29411 | Palmitoyl-protein thioesterase 1 (Ppt) | 1.052246 | (p = 0.5199114) | 0.882921 | (p = 0.192733) |
| Foa1 | NM_012742.1 | 25098 | Forkhead box A1 | 1.489049↑ | (p = 0.001314) | 0.831777 | (p = 0.136951) |
| Hnf4A | NM_022180.1 | 25725 | Hepatocyte nuclear factor 4, alpha (Hnf4alpha, Hnf4a) | 0.912061 | (p = 0.377142) | 1.357585↑ | (p = 0.003965) |
| Mbp | NM_001108821.1 | 171078 | MLX interacting protein-like (ChREBP, WS-bHLH, Wbcr14, bHLHd14) | 1.976840↑ | (p = 1.9E-15) | 0.724559↓ | (p = 0.000044) |
lipid clearance, as well as transcription factors influencing lipid metabolism, whose expression was significantly altered in response to NDGA treatment in these three tissue types.

As reported previously, and confirmed here, after 16 weeks on a diet in which about 67 % of kcals are derived from fructose, the rats developed hyperinsulinemia (insulin resistance), hypertriglyceridemia and hepatic steatosis [47, 56, 68]. Additionally, our results demonstrated that the dietary administration of NDGA greatly attenuated the HFrD induced hepatic steatosis and plasma triglyceride levels. Given that hepatic steatosis and dyslipidemia result from an imbalance in lipid homeostasis in the liver when fatty acid uptake or de novo lipogenesis outweighs lipid oxidation or export. Accordingly, we first examined the effects of HFrD and HFrD + NDGA feeding on the expression of key genes involved in hepatic fatty acid uptake, fatty acid oxidation and thioesterification/activation of fatty acids catalyzed by acyl-CoA synthetase enzymes, which is required for fatty acid catabolism, de novo lipogenesis and remodeling of biological membranes. Whereas expression of fatty acid transporter Slc27a1 (FATP1) was not affected by high-fructose feeding, expression of Slc27a2 (FATP2) was significantly upregulated. Likewise, although HFrD + NDGA treatment had no effect on the mRNA levels of Slc27a1, co-treatment with NDGA prevented the HFrD-induced expression of Slc27a2. We further observed that NDGA upregulated the expression of several genes for enzymes involved in fatty acid thiolation/activation (synthesis of acyl-CoAs); it increased the expression of acyl-CoA synthetase long-chain family member 1 (Acsl1) and acyl-CoA synthetase medium-chain family member 3 (Acsm3), but attenuated the levels of acyl-CoA synthetase long-chain family member 4 (Acsl4) and acyl-CoA synthetase short-chain family member 2 (Acss2). These acetyl-CoA synthetases vary in their substrate specificity and partitioning of fatty acids towards diverse cellular metabolic pathways. Acsl1 shows preference for long chain saturated and monounsaturated fatty acids C16 to C18, whereas Acs14 shows specificity for polyunsaturated fatty acids C20:4 and C20:5 [65]. Acsn3 acts on medium

**Table 1** Hepatic genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA) (Continued)

| Gene  | Description                                      | Expression (HFrD) | Expression (HFrD-NDGA) |
|-------|--------------------------------------------------|-------------------|------------------------|
| Nr1h3 | Nuclear receptor subfamily H, member 3 (LXRalpha) | 0.980054          | 1.208346†             |
|       | (p = 0.851777)                                   | (p = 0.041273)    |
| Ppara | Peroxisome proliferator activated receptor alpha (PPAR) | 1.009554          | 1.760026†             |
|       | (p = 0.946257)                                   | (p = 0.000067)    |
| Ppard | Peroxisome proliferator activated receptor delta (Ppard) | 0.843786          | 0.753122               |
|       | (p = 0.226207)                                   | (p = 0.144411)    |                       |
|       | and                                              |                   | 1.189417               |
|       | (p = 0.204488)                                   | (p = 0.029129)    |                       |
| Ppargc1a | Peroxisome proliferator activated receptor gamma, coactivator 1 alpha (Ppargc1a) | 0.738155          | —                      |
|       | (p = 0.120955)                                   |                   |                       |
| Ppargc1b | Peroxisome proliferator activated receptor, coactivator 1 beta (Ppargc1b, Perc) | 0.969931          | 1.534911†             |
|       | (p = 0.815666)                                   | (p = 0.012486)    |                       |
| Srebf1 | Sterol regulatory element binding transcription factor 1 (ADD-1, ADD1, SREBP-1, SREBP-1c, Srebpl) | 1.604384†         | 0.8782                 |
|       | (p = 0.000000)                                   | (p = 0.129048)    | and                   |
|       | and                                              | and               | 1.456601†             |
|       | (p = 0.000000)                                   | (p = 0.017444)    | 0.934259              |
|       | and                                              | and               | (p = 0.479001)         |
| Srebf2 | Sterol regulatory element binding transcription factor 2 (SREBP-2, SREBP-2-retired, Srebfp2) | 0.732005*         | 1.071545               |
|       | (p = 0.000761)                                   | (p = 0.478687)    | and                   |
| Xbp1  | X-box binding protein 1 (HTF)                    | 1.148942          | 0.807070†             |
|       | (p = 0.076252)                                   | (p = 0.016697)    |

by high-fructose feeding, expression of Slc27a2 (FATP2) was significantly upregulated. Likewise, although HFrD + NDGA treatment had no effect on the mRNA levels of Slc27a1, co-treatment with NDGA prevented the HFrD-induced expression of Slc27a2. We further observed that NDGA upregulated the expression of several genes for enzymes involved in fatty acid oxidation, including Cpt1b, Cpt2, Acox1, Acdvl, Eci and Ehabd. In addition, our data provide evidence that NDGA differentially impacted the PPARα target genes for the enzymes involved in fatty acid thiolation/activation (synthesis of acyl-CoAs); it increased the expression of acyl-CoA synthetase long-chain family member 1 (Acs11) and acyl-CoA synthetase medium-chain family member 3 (Acsn3), but attenuated the levels of acyl-CoA synthetase long-chain family member 4 (Acs14) and acyl-CoA synthetase short-chain family member 2 (Acs2). These acetyl-CoA synthetases vary in their substrate specificity and partitioning of fatty acids towards diverse cellular metabolic pathways. Acs11 shows preference for long chain saturated and monounsaturated fatty acids C16 to C18, whereas Acsn3 shows specificity for polyunsaturated fatty acids C20:4 and C20:5 [65]. Acsn3 acts on medium
| Gene symbol/GenBank accession/GenID | Entrez gene name | HFrD/Chow (Fold-change) | HFrD-NDGA/HFrD (Fold-change) |
|-----------------------------------|------------------|-------------------------|-----------------------------|
| **Fatty Acid Transport**          |                  |                         |                             |
| Slc27a1                           | Soluble carrier family 27 (fatty acid transporter), member 1 (FATP1) | 1.163926 \( (p = 0.067083) \) | 0.603296 \( (p = 0.000002) \) |
| Slc27a2                           | Soluble carrier family 27 (fatty acid transporter), member 2 (FATP2) | 0.8357 \( (p = 0.727766) \) | 6.826838 \( (p = 7.06E-28) \) |
| **Acyl-CoA Synthetases**          |                  |                         |                             |
| Acs1                              | Acyl-CoA synthetase long-chain family member 1 \( (ACS, Acas, COAA, Fac12) \) | 0.929637 \( (p = 0.400503) \) | 0.818346 \( (p = 0.04231) \) |
| Acs4                              | Acyl-CoA synthetase long-chain family member 4 \( (ACS4, Fac14) \) | 1.060922 \( (p = 0.54153) \) | 1.353734 \( (p = 0.125592) \) |
| Acsm3                             | Acyl-CoA synthetase medium-chain family member 3 \( (Sa, Sah) \) | 1.134565 \( (p = 0.63539) \) | 1.518789 \( (p = 0.055276) \) |
| Acss2                             | Acyl-CoA synthetase short chain family member 2 \( (Acss2) \) | 1.011241 \( (p = 0.898282) \) | 1.280275 \( (p = 0.002825) \) |
| **Fatty Acid Oxidation**          |                  |                         |                             |
| Cpt1a                             | Carnitine palmitoyltransferase 1a, liver \( (CPT-1a) \) | 1.067497 \( (p = 0.448414) \) | 0.449902 \( (p = 5.12E-08) \) |
| Cpt1b                             | Carnitine palmitoyltransferase 1b, muscle \( (CPT-1B, M-CPT1) \) | 0.828098 \( (p = 0.041576) \) | 0.715237 \( (p = 0.000001) \) |
| Cpt1c                             | Carnitine palmitoyltransferase 1c \( (CPT 1C, CPT1-B, CPTI-B) \) | 1.086711 \( (p = 0.58947) \) | 1.392775 \( (p = 0.007650) \) |
| Cpt2                              | Carnitine palmitoyltransferase 2 \( (CPTII) \) | 1.095366 \( (p = 0.448414) \) | 0.449902 \( (p = 5.12E-08) \) |
| Acox1                             | Acyl-CoA oxidase, palmitoyl \( (RATACOA1) \) | 0.942485 \( (p = 0.405327) \) | 1.239981 \( (p = 0.026649) \) |
| Acox2                             | Acyl-CoA dehydrogenase, long chain \( (ACOADA, LCAD) \) | 1.08506 \( (p = 0.607105) \) | 0.897447 \( (p = 0.286828) \) |
| Acd1                              | Acyl-CoA dehydrogenase, C-4 to C-12 straight chain \( (MCAD) \) | 1.018954 \( (p = 0.786051) \) | 1.120494 \( (p = 0.185916) \) |
| Acdm                              | Acyl-CoA dehydrogenase, C-2 to C-3 short chain \( (Scad) \) | 0.947987 \( (p = 0.686716) \) | 1.163831 \( (p = 0.106741) \) |
| Acads                             | Acyl-CoA dehydrogenase, short/branched chain | 0.767644 \( (p = 0.006663) \) | 1.578611 \( (p = 0.000470) \) |
| Acadvl                            | Acyl-CoA dehydrogenase very long chain \( (VLCAD) \) | 1.02304 \( (p = 0.81081) \) | 1.104065 \( (p = 0.242381) \) |
| Eci1                              | Enoyl-CoA delta isomerase 1 \( (Deci) \) | 1.028304 \( (p = 0.734099) \) | 1.203436 \( (p = 0.11201) \) |
| Echs1                             | Enoyl-CoA hydratase, short chain 1, mitochondrial | 0.890438 \( (p = 0.269622) \) | 0.970797 \( (p = 0.801854) \) |
Table 2  Skeletal muscle genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA) (Continued)

| Gene   | Accession | ID       | Description                                                      | HFrD | HFrD-NDGA |
|--------|-----------|----------|------------------------------------------------------------------|------|-----------|
| Ehhadh | NM_133606.1 | 171142   | Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase                | 1.255433† | 4.521567† |
|        |           |          |                                                                  | (p = 0.004941) | (p = 1.81E-20) |
| Eci2   | NM_001006966.1 | 291075   | Enoyl-CoA delta isomerase 2 (Peci)                               | 0.899414 | 0.74287↓ |
|        |           |          |                                                                  | (p = 0.120824) | (p = 0.000344) |
|        |           |          | **Fatty Acid Synthesis/ De Novo Lipogenesis**                    |      |           |
| Gckr   | NM_013120.2 | 25658    | Glucokinase (hexokinase 4) regulator (GLRE)                       | 1.07709 | 2.031414† |
|        |           |          |                                                                  | (p = 0.694603) | (p = 0.000004) |
| Gck    | NM_012565.1 | 24385    | Glukokinase (GLUKA, RNGK2)                                       | 0.959106 | 1.706245↑ |
|        |           |          |                                                                  | (p = 0.801909) | (p = 0.000131) |
| Pklr   | NM_012624.3 | 24651    | Pyruvate kinase, liver and RBC (PK1, PKL, Pklg)                  | 1.013481 | 1.252908 ↓|
|        |           |          |                                                                  | (p = 0.932088) | (p = 0.073772) |
| Acly   | NM_016897.2 | 24159    | ATP citrate lyase (ACL, Clatp)                                   | 0.998999 | 0.737265↓ |
|        | NM_00111095.1 | 24159    |                                                                  | (p = 0.98697) | (p = 0.000026) |
| Fasn   | NM_01332.1 | 50761    | Fatty acid synthase                                               | 0.706952↓ | 0.930935↓ |
|        |           |          |                                                                  | (p = 0.00244) | (p = 0.545657) |
| Me1    | NM_012600.2 | 24552    | Malic enzyme 1, NADP(+)-dependent, cytosolic (MOD1)              | 0.822072 | 1.112270↑ |
|        |           |          |                                                                  | (p = 0.082114) | (p = 0.365453) |
| Me2    | NM_00111095.1 | 307270   | Malic enzyme 2, NAD(+)-dependent, mitochondrial                 |      |           |
|        |           |          |                                                                  |      |           |
| Scd1   | NM_139192.2 | 246074   | Stearyl-Coenzyme A desaturase 1                                  | 1.31285↑ | 0.761013↑ |
|        |           |          |                                                                  | (p = 0.002357) | (p = 0.065913) |
| Elovl1 | NM_001044275.1 | 67953.2 | ELOVL fatty acid elongase 1                                      | 1.011133 | 0.639064↓ |
|        |           |          |                                                                  | (p = 0.897404) | (p = 5.49E-08) |
|        |           |          | and                                                             | 0.943348 | 0.584865↓ |
|        |           |          |                                                                  | (p = 0.539378) | (p = 0.000002) |
| Elovl2 | NM_001109118.1 | 498728  | ELOVL fatty acid elongase 2                                      | 2.709103 | 1.216575↑ |
|        |           |          |                                                                  | (p = 0.626956) | (p = 0.73873) |
| Elovl4 | NM_001911796.1 | 315851  | ELOVL fatty acid elongase 4                                      | 0.831144 | 0.905935↑ |
|        | XM_001062735.2 |         |                                                                  | (p = 0.17275) | (p = 0.619544) |
| Elovl5 | NM_134382.1 | 171400   | ELOVL fatty acid elongase 5 (rELO1)                              | 0.732669↓ | 0.768796↓ |
|        |           |          |                                                                  | (p = 0.000051) | (p = 0.002744) |
| Elovl6 | NM_134383.2 | 171402   | ELOVL fatty acid elongase 6 (Loe2, rELO2)                        | 1.034949 | 0.993481↓ |
|        |           |          |                                                                  | (p = 0.742391) | (p = 0.969926) |
|        |           |          | and                                                             | 0.974533 | 1.246617↓ |
|        |           |          |                                                                  | (p = 0.82477) | (p = 0.381630) |
| Fads1  | NM_053445.2 | 84575    | Fatty acid desaturase 1                                          | 1.241893↑ | 0.760080↓ |
|        |           |          |                                                                  | (p = 0.044164) | (p = 0.006978) |
| Fads2  | NM_031344.2 | 83512    | Fatty acid desaturase 2 (Fadsd6)                                 | 2.161421↑ | 0.699797↓ |
|        |           |          |                                                                  | (p = 8.54E-12) | (p = 0.000734) |
| Mlcyd  | NM_053477.1 | 85239    | Malonyl-CoA decarboxylase                                        | 1.050798 | 0.988309↓ |
|        |           |          |                                                                  | (p = 0.506797) | (p = 0.909295) |
Table 2  Skeletal muscle genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA) (Continued)

| Gene        | Description                                                                 | HFrD-NDGA | HFrD |
|-------------|------------------------------------------------------------------------------|-----------|------|
| Triglyceride (TG) Synthesis/VLDL-TG Assembly |
| **1-Acylglycerol-3-phosphate O-acyltransferase 1** |
| Agpat1      | Acyl: NM_212458.1 ID: 406165                                                | 0.992486  | 1.30654† |
| **1-Acylglycerol-3-phosphate O-acyltransferase 2** |
| Agpat2      | Acyl: NM_00107821.1 ID: 311821                                               | 1.090764  | 0.732075† |
| **1-Acylglycerol-3-phosphate O-acyltransferase 3** |
| Agpat3      | Acyl: NM_00106378.1 ID: 311821                                               | 0.943450  | 0.954861 |
| **1-Acylglycerol-3-phosphate O-acyltransferase 6 (RGD1310520)** |
| Agpat6      | Acyl: NM_001047849.1 ID: 305166                                               | 0.976834  | 1.114009 |
| **1-Acylglycerol-3-phosphate O-acyltransferase 9** |
| Agpat9      | Acyl: 001025670.1 ID: 305166                                                 | 0.753988  | 0.791921† |
| Monoacylglycerol O-acyltransferase 1 |
| Mogat1      | Acyl: NM_001108803.1 ID: 363261                                               | 0.875509  | 0.592216† |
| **Diacylglycerol O-acyltransferase 1 (ARAT, Dgat)** |
| Dgat1       | Acyl: NM_053437.1 ID: 84497                                                   | 0.928218  | 1.485906† |
| **Diacylglycerol O-acyltransferase 2 (ARAT)** |
| Dgat2       | Acyl: NM_00102345.1 ID: 252900                                               | 0.911253  | 1.451837† |
| ADP-riboseylation factor 3 (AC1-253) |
| Arf3        | Acyl: NM_080904.2 ID: 140940                                                  | 1.119282  | 0.530910 |
| Cholesterol Synthesis/Metabolism |
| **Acetyl-CoA acetyltransferase 2 (Acat3, Ab2-076)** |
| Acat2       | Acyl: NM_001006995.1 ID: 308100                                               | 0.952536  | 0.989649 |
| **3-Hydroxy-3-methylglutaryl-CoA reductase (3H3M)** |
| Hmgcr       | Acyl: NM_013134.2 ID: 25675                                                  | 1.070248  | 0.663322† |
| **Insulin induced gene 1** |
| Insig 1     | Acyl: NM_022392.1 ID: 64194                                                  | 1.242984† | 1.549161† |
| **Insulin induced gene 2** |
| Insig 2     | Acyl: NM_178091.4 ID: 288985                                                 | 0.864261  | 1.265492 |
| **Low density lipoprotein receptor (LDLRA)** |
| Ldr         | Acyl: NM_175762.2 ID: 300438                                                  | 0.994617  | 0.996123 |
| **Mevalonate kinase (Lrbp)** |
| Mvk         | Acyl: NM_031063.1 ID: 81727                                                  | 1.014383  | 1.129775 |
| **Niemann-Pick disease, type C1 (Cdg2)** |
| Npc1        | Acyl: NM_00002025.11 ID: 266732                                              | 1.002647  | 0.806589 |
| Proteins Involved in Lipid Clearance |
| **ATP-binding cassette, subfamily A (ABC1), member 4 (ABCR)** |
| Abca4       | Acyl: NM_0110772.1 ID: 310836                                                | —         | —     |
| **ATP-binding cassette, subfamily B (MDR/TAP), member 4 (Mdr2, Pgy3)** |
| Abcb4       | Acyl: NM_012690.1 ID: 24891                                                  | 1.001665  | 1.352659† |
| **ATP-binding cassette, subfamily B (MDR/TAP), member 11 (Bsep, Spgpp)** |
| Abcb11      | Acyl: NM_031760.1 ID: 83569                                                  | 0.975717  | 2.314507† |

*Zhang et al. Nutrition & Metabolism (2016) 13:63*
| Gene | Accession | ID  | Description | Ratio (HFrD vs HFrD-NDGA) | p-Value (HFrD vs HFrD-NDGA) |
|------|-----------|-----|-------------|--------------------------|-----------------------------|
| Abcc3 | NM_080581.1 | 140668 | ATP-binding cassette, subfamily C (CFTR/MRP), member 3 (Mlp2, Mrp3) | 1.13094 (p = 0.112959) | 0.554283↓ (p = 3.47E-08) |
| Abcc6 | NM_031013.1 | 81642 | ATP-binding cassette, subfamily C (CFTR/MRP), member 6 (Mlp6) | 1.016698 (p = 0.931493) | 2.173900↑ (p = 0.000012) |
| Abcd1 | NM_001108821.1 | 363516 | ATP-binding cassette, subfamily D (ALD), member 3 (RGD1562128) | 0.966064 (p = 0.685132) | 1.77834 (p = 0.073443) |
| Abcd3 | NM_012804.1 | 25270 | ATP-binding cassette, subfamily D (ALD), member 3 (PMP70, Pxmp1) | 1.071230 (p = 0.315252) | 1.178834 (p = 0.074443) |
| Abcg2 | NM_181381.2 | 312382 | ATP-binding cassette, subfamily G (WHITE), member 2 (BCRP1) | 0.940064 (p = 0.737683) | – |
| Abcg5 | NM_053754.2 | 114628 | ATP-binding cassette, subfamily G (WHITE), member 5 | 0.980266 (p = 0.916333) | 0.810473↓ (p = 0.506217) |
| Apoa4 | NM_012737.1 | 25080 | Apolipoprotein A-IV (Apo-AIV, ApoA-IV, ApoAIV) | 0.886124 (p = 0.637386) | 3.570020↑ (p = 2.22E-17) |
| Apob | NM_019287.2 | 54225 | Apolipoprotein B (Aa1064, AC1-060, Apo B-100, ApoB-100, ApoB-48) | 0.726099 (p = 0.575237) | 5.457586↑ (p = 5.48E-13) |
| Apoc2 | NM_001085352.1 | 292697 | Apolipoprotein C-II (RGD1560725) | 0.935620 (p = 0.363938) | 3.570200↑ (p = 2.22E-17) |
| Apoc3 | NM_01085352.1 | 292697 | Apolipoprotein C-III (ApoC-III, apo-CIII) | 0.912894 (p = 0.302897) | 8.022169↑ (p = 6.3E-25) |
| Apoe | NM_012501.1 | 24207 | Apolipoprotein E (APOEA) | 1.062438 (p = 0.461893) | 1.200139↑ (p = 0.030468) |
| ApoF | NM_001024351.1 | 500761 | Apolipoprotein F | – | – |
| Lpl | NM_012498.2 | 24539 | Lipoprotein lipase | 0.985218 (p = 0.852647) | 0.543880↓ (p = 4.93E-12) |
| Vldlr | NM_013155.2 | 25696 | Very low density lipoprotein receptor | 1.062438 (p = 0.461893) | 1.718766↑ (p = 0.784789) |
| Ppt1 | NM_022502.2 | 29411 | Palmitoyl-protein thioesterase 1 (Ppt) | 0.959614 (p = 0.555592) | 0.505612↓ (p = 5.6E-15) |
| Foxa1 | NM_012742.1 | 25098 | Forkhead box A1 | 0.861648 (p = 0.593030) | 0.790538↓ (p = 0.286379) |
| Hnf4a | NM_022180.1 | 25735 | Hepatocyte nuclear factor 4, alpha (Hnf4alpha, Hnf4a) | 0.969862 (p = 0.899345) | 0.897382↓ (p = 0.784789) |
| Mibpi | NM_133552.1 | 171078 | MLX interacting protein-like (ChRBP, WS-bHLH, Wbsec14, bHLHid14) | 0.648171↑ (p = 1.16E-08) | 0.9323704 (p = 0.439391) |
| Nrf1h3 | NM_031627.2 | 58852 | Nuclear receptor subfamily 1, group H, member 3 (LXRalpha) | 1.002888 (p = 0.964985) | 1.708129↑ (p = 0.000001) |
chain fatty acids C4 to C11 and catalytic function of Acss2 is to catalyze the activation of acetate (short chain) for use in lipid synthesis. Since C4-C18 fatty acids are mainly oxidized via mitochondrial β-oxidation, it is likely that NDGA induces the expression of Acsl1 and Acsm3 in an effort to promote increased channeling of the hepatic medium and long chain fatty acids for their catabolism via mitochondrial β-oxidation. Besides, we observed that NDGA treatment increased the gene expression of PPARα transcription factor, a member of the nuclear hormone receptor superfamily [60]. It is considered a master regulator of oxidative catabolism of fatty acids for energy production, is expressed at high levels in metabolically active tissues such as heart, liver, skeletal muscle and kidney, and controls the transcription of many genes involved in mitochondrial and peroxisomal β-oxidation and microsomal ω-oxidation of fatty acids, with liver being its major site of action [60, 64]. Some of the genes involved in fatty acid uptake and activation, such as SLC27A2, Acsl1, Acsl4, Acsm3 and Acss2, are also the targets of PPARα [64].

In this study, NDGA also markedly increased the expression of both PPARα and PPARβ/δ in skeletal muscle, which was accompanied by increased expression of several genes for enzymes involved in fatty acid uptake, activation and oxidation, including Cpt1a, Acox1, Acadsb, Eci, Ehldah, FATP2 (Slc27a2) and Acss2. Few genes were downregulated in response to NDGA treatment, including Cpt1a, Cpt1b, Eci2, Acsl2 and FATP1 (Slc27a1). It is unclear why NDGA treatment decreased the expression of three fatty acid catabolizing genes, Cpt1a, Cpt1b and Eci2. Also, it is surprising that NDGA treatment decreased the expression of the glucose transporter Glut4, resulting in animals becoming insulin resistant and glucose intolerant [70]. In contrast, diet-induced insulin resistance was prevented in PPARα-/-mice despite the development of obesity. Our previous

### Table 2: Skeletal muscle genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA) (Continued)

| Gene | Description | NDGA/HFrD-NDGA (fold change) | p-value |
|------|-------------|-----------------------------|---------|
| Ppara | Peroxisome proliferator activated receptor alpha (PPAR) | 0.897809 | 2.537218† |
| Ppard | Peroxisome proliferator activated receptor delta (Pparb) | 1.000165 | 1.428902† |
| Ppargc1a | Peroxisome proliferator activated receptor gamma | 0.801471↓ | 0.924624 |
| Ppargc1b | Peroxisome proliferator activated receptor gamma, coactivator 1 alpha (Ppargc1) | 0.719326 | 1.479666 |
| Srebfl | Sterol regulatory element binding transcription factor | 0.986205 | 1.837534† |
| Srebfl2 | Sterol regulatory element binding transcription factor | 1.028776 | 0.82597 |
| Xbp1 | X-box binding protein 1 (HTF) | 1.055655 | 1.317409† |
### Table 3 Adipose tissue genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA)

| Gene symbol/GenBank accession/Gene ID | Entrez gene name | HFrD/Chow (Fold-change) | HFrD-NDGA/HFrD (Fold-change) |
|--------------------------------------|-----------------|-------------------------|-----------------------------|
| Slc27a1 Acc: NM_053580.2 ID: 94172   | Soluble carrier family 27 (fatty acid transporter), member 1 (FATP1) | 0.626371† (p = 0.000005) | 1.243856† (p = 0.035818) |
| Slc27a2 Acc: NM_031736.1 ID: 65192 | Soluble carrier family 27 (fatty acid transporter), member 2 (FATP2) | — | 0.843521 (p = 0.704995) |
| Acss2 Acc: NM_001107793.1 ID: 311569 | Acyl-CoA synthetase short chain family member 2 (Acss2) | 0.966705 (p = 0.717211) | 0.884133 (p = 0.161879) |
| Acox1 Acc: NM_017340.2 ID: 506811  | Acyl-CoA oxidase, palmitoyl (RATACOA1) | 1.291301† (p = 0.000954) | 1.086216 (p = 0.293942) |
| Acadm Acc: NM_016986.2 ID: 24158   | Acyl-CoA dehydrogenase, C-4 to C-12 straight chain (MCAD) | 1.017514 (p = 0.84005) | 0.917314 (p = 0.340538) |
| Acacd Acc: NM_022512.1 ID: 64304   | Acyl-Coa dehydrogenase, C-2 to C-3 short chain (Scad) | 0.645793† (p = 0.000149) | 1.280965 (p = 0.065028) |
| Acaddb Acc: NM_013084.1 ID: 25618  | Acyl-Coa dehydrogenase, short/branched chain | 0.775064 (p = 0.065038) | 1.282204† (p = 0.00099) |
| Acaddv Acc: NM_012891.1 ID: 25363  | Acyl-Coa dehydrogenase very long chain (VLCAD) | 0.785093† (p = 0.006311) | 1.282064† (p = 0.003725) |
| Eci1 Acc: NM_017306.4 ID: 29740     | Enoyl-CoA delta isomerase 1 (DecI) | 0.978986 (p = 0.737175) | 0.971389 (p = 0.001192) |
| Echs1 Acc: NM_078623.2 ID: 140547  | Enoyl-CoA hydratase, short chain 1, mitochondrial | 0.764837† (p = 0.000566) | 1.220593 (p = 0.080591) |
| Ethdh Acc: NM_133606.1 ID: 171142  | Enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase | 0.647705† (p = 0.000141) | 1.219944 (p = 0.618767) |
| Gene | Accession | ID | Description | Log2 Fold Change (HFrD vs. NDGA) | p-value (HFrD vs. NDGA) | Log2 Fold Change (HFrD vs. Control) | p-value (HFrD vs. Control) |
|------|-----------|----|-------------|-------------------------------|------------------------|-----------------------------------|----------------------------|
| Eci2 | Acc: NM_001006966.1 | ID:291075 | Enoyl-CoA delta isomerase 2 (Peci) | 0.899414 | (p = 0.120824) | 0.74287 | (p = 0.000344) |
| Gckr | Acc: NM_013120.2 | ID: 25658 | Glucokinase (hexokinase 4) regulator (GLRE) | 0.755501 | (p = 0.053196) | 1.126918 | (p = 0.490323) |
| Gck | Acc: NM_012565.1 | ID: 24385 | Glukokinase (GLUKA, RNGK2) | 4.265985 | (p = 6.89E-18) | 0.302628 | (p = 4.47E-11) |
| Pklr | Acc: NM_012624.3 | ID: 24651 | Pyruvate kinase, liver and RBC (PK1, PKL, Pklg) | 2.097495 | (p = 0.000451) | 0.895746 | (p = 0.143597) |
| Acly | Acc: NM_016987.2 | | ATP citrate lyase (ACL, Clatp) | 1.295435 | (p = 0.000403) | 0.904824 | (p = 0.357733) |
| Fasn | Acc: NM_01332.1 | ID: 50761 | Fatty acid synthase | 0.755501 | (p = 0.053196) | 1.126918 | (p = 0.490323) |
| Me1 | Acc: NM_012600.2 | ID: 24552 | Malic enzyme 1, NADP(+)-dependent, cytosolic (MOD1) | 0.847973 | (p = 0.065373) | 0.990152 | (p = 0.920281) |
| Me2 | Acc: NM_001111095.1 | ID: 307270 | Malic enzyme 2, NAD(+)-dependent, mitochondrial | — | — | — | — |
| Scd1 | Acc: NM_139192.2 | ID: 246074 | Stearyl-Coenzyme A desaturase 1 | 9.92997 | (p = 3.10E-28) | 3.67533 | (p = 0.00E+00) |
| Elov1 | Acc: NM_001044275.1 | ID: 67953.2 | ELOVL fatty acid elongase 1 | 0.696973 | (p = 0.000451) | 1.502326 | (p = 0.000451) |
| Elov2 | Acc: NM_001091118.1 | ID: 498728 | ELOVL fatty acid elongase 2 | 0.712072 | (p = 0.000451) | 0.330644 | (p = 0.176175) |
| Elov4 | Acc: NM_001191796.1 | | ELOVL fatty acid elongase 4 | 1.053677 | (p = 0.000451) | 0.950803 | (p = 0.000451) |
| Elov5 | Acc: NM_134382.1 | ID: 171400 | ELOVL fatty acid elongase 5 (fELO1) | 1.027579 | (p = 0.000451) | 2.101966 | (p = 0.000451) |
| Elov6 | Acc: NM_134383.2 | ID: 171402 | ELOVL fatty acid elongase 6 (Lee2, rELO2) | 0.511033 | (p = 0.000127) | 1.436011 | (p = 0.000127) |
| Fads1 | Acc: NM_053445.2 | ID: 84575 | Fatty acid desaturase 1 | 1.16415 | (p = 0.000451) | 0.828712 | (p = 0.000451) |
| Fads2 | Acc: NM_0313442.2 | ID: 83512 | Fatty acid desaturase 2 (Fadsd6) | 1.036468 | (p = 0.000451) | 0.890867 | (p = 0.000451) |
| Mlcyd | Acc: NM_053477.1 | ID: 85239 | Malonyl-CoA decarboxylase | 1.06015 | (p = 0.000451) | 0.800024 | (p = 0.000451) |

Triglyceride (TG) Synthesis/VLDL-TG Assembly

Zhang et al. Nutrition & Metabolism (2016) 13:63
Page 18 of 26
| Gene          | Accession       | ID      | Description                                      | HFrD to HFrD-NDGA  |
|--------------|----------------|---------|--------------------------------------------------|-------------------|
| Agpat1       | NM_212458.1    | 406165  | 1-Acylglycerol-3-phosphate O-acyltransferase 1   | 1.733174†          |
|              |                |         |                                                  | (p = 0.000011)     |
| Agpat2       | NM_001107821.1 | 311821  | 1-Acylglycerol-3-phosphate O-acyltransferase 2   | 0.890825           |
|              |                |         |                                                  | (p = 0.154834)     |
| Agpat3       | NM_001106378.1 | 311821  | 1-Acylglycerol-3-phosphate O-acyltransferase 3   | 0.625706↓          |
|              |                |         |                                                  | (p = 0.004796)     |
| Agpat6       | NM_001047849.1 | 305166  | 1-Acylglycerol-3-phosphate O-acyltransferase 6   | 0.668305↓          |
|              |                |         |                                                  | (p = 0.00001)      |
| Agpat9       | 001025670.1    | 305166  | 1-Acylglycerol-3-phosphate O-acyltransferase 9   | 0.702126↓          |
|              |                |         |                                                  | (p = 0.007365)     |
| Mogat1       | NM_001108803.1 | 363261  | Monoacylglycerol O-acyltransferase 1             | 0.911577           |
|              |                |         |                                                  | (p = 0.405954)     |
| Dgat1        | NM_001012345.1 | 252900  | Diacylglycerol O-acyltransferase 1 (ARAT, Dgat) | 1.000764           |
|              |                |         |                                                  | (p = 0.992838)     |
| Dgat2        | NM_001012345.1 | 252900  | Diacylglycerol O-acyltransferase 2 (ARAT)        | 0.766526↓          |
|              |                |         |                                                  | (p = 0.033377)     |
| Arf3         | NM_080904.2    | 140940  | ADP-ribosylation factor 3 (AC1-253)              | 1.253088↑          |
|              |                |         |                                                  | (p = 0.000991)     |
| Acat2        | NM_001006995.1 | 308100  | Acetyl-CoA acetyltransferase 2 (Acat3, Ab2-076)  | 1.149942           |
|              |                |         |                                                  | (p = 0.064026)     |
| Hmgcr        | NM_013134.2    | 25675   | 3-Hydroxy-3-methylglutaryl-CoA reductase (3H3M)  | 0.614003↓          |
|              |                |         |                                                  | (p = 0.000734)     |
| Insig 1      | NM_022392.1    | 64194   | Insulin induced gene 1                           | 1.046145           |
|              |                |         |                                                  | (p = 0.573906)     |
| Insig 2      | NM_178091.4    | 298885  | Insulin induced gene 2                           | 0.823541           |
|              |                |         |                                                  | (p = 0.133816)     |
| Ldr          | NM_175762.2    | 300438  | Low density lipoprotein receptor (LDLRA)         | 0.761982           |
|              |                |         |                                                  | (p = 0.148211)     |
| Mek          | NM_031063.1    | 81727   | Mevalonate kinase (Lrbp)                         | 1.024571           |
|              |                |         |                                                  | (p = 0.839357)     |
| Npc1         | NM_001002025.11| 266732  | Niemann-Pick disease, type C1 (Cdig2)            | 0.838672           |
|              |                |         |                                                  | (p = 0.861612)     |
| Abca4        | NM_00110772.1  | 310836  | ATP-binding cassette, subfamily A (ABC1), member 4 (ABCR) | —       |
| Abcb4        | NM_012690.1    | 24891   | ATP-binding cassette, subfamily B (MDR/TAP), member 4 (Mdr2, Pgy3) | 1.290231           |
|              |                |         |                                                  | (p = 0.284859)     |
| Abcb11       | NM_031760.1    | 83569   | ATP-binding cassette, subfamily B (MDR/TAP), member 11 (Biep, Spgpc) | 0.693218           |
|              |                |         |                                                  | (p = 0.05412)      |
### Table 3
Adipose tissue genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA) (Continued)

| Gene | Accession | ID      | Description                                                                 | HFrD      | HFrD-NDGA |
|------|------------|---------|------------------------------------------------------------------------------|------------|-----------|
| Abcc3 | NM_080581.1 | 140668  | ATP-binding cassette, subfamily C (CFTR/MRP), member 3 (Mrp2, Mrp3)       | 0.930144   | 0.930223  |
| Abcc6 | NM_031013.1 | 81642   | ATP-binding cassette, subfamily C (CFTR/MRP), member 6 (Mrp6)              | 1.044104   | 0.953551  |
| Abcd1 | NM_001108821.1 | 363516 | ATP-binding cassette, subfamily D (ALD), member 3 (RGD1562128)           | 0.981591   | 0.973671  |
| Abcd3 | NM_012804.1 | 25270   | ATP-binding cassette, subfamily D (ALD), member 3 (PMP70, Pxmp1)         | 0.775986 ↓ | 1.067058 |
| Abcg2 | NM_181381.2 | 312382  | ATP-binding cassette, subfamily G (WHITE), member 2 (BCRP1)                | 0.840673   | 1.966469  |
| Abcg5 | NM_053754.2 | 114628  | ATP-binding cassette, subfamily G (WHITE), member 5                        | 1.289574   | 0.839246  |
| Apoa4 | NM_012737.1 | 25080   | Apolipoprotein A-IV (Apo-AIV, ApoA-IV, ApoAIV)                              | 2.057009 ↑ | 0.532413 ↓ |
| Apob | NM_019287.2 | 54225   | Apolipoprotein B (Aa1064, AC1-060, Apo B-100, ApoB-100, ApoB-48)          | 0.90111    | 1.187596  |
| Apoc2 | NM_01085352.1 | 292697 | Apolipoprotein C-II (RGD1560725)                                            | 0.684698 ↓ | 1.307856 ↑ |
| Apoc3 | NM_012501.1 | 24207   | Apolipoprotein C-III (ApoC-III, apo-CIII)                                   | 0.6722 ↓   | 0.0486999 ↓ |
| Apoe | NM_138828.2 | 25728   | Apolipoprotein E (APOEA)                                                   | 1.485673 ↑ | 0.778654 ↓ |
| Apof | NM_001024351.1 | 500761 | Apolipoprotein F                                                            | —          | —         |
| Lpl  | NM_012498.2 | 24539   | Lipoprotein lipase                                                          | 1.135422   | 0.812916 ↓ |
| Vldlr | NM_013155.2 | 25696   | Very low density lipoprotein receptor                                       | 0.6722 ↓   | 1.096751 |
| Ppt1 | NM_022502.2 | 29411   | Palmitoyl-protein thioesterase 1 (Ppt)                                       | 0.9252     | 1.076592 |
| Foxa1 | NM_012742.1 | 25098   | Forkhead box A1                                                            | 0.828962   | 1.067287 |
| Hnf4a | NM_022180.1 | 25735   | Hepatocyte nuclear factor 4, alpha (Hnf4alpha, Hnf4a)                       | 1.208695   | 0.934321  |
| Mki67l | NM_133552.1 | 171078  | MLX interacting protein-like (ChREBP, WS-bHLH, Wbscr14, bHLHd14)           | 1.019326   | 1.23554 ↑ |
| Nr1h3 | NM_031627.2 | 58852   | Nuclear receptor subfamily 1, group H, member 3 (LXRalpha)                  | 0.898224   | 1.22274 ↑ |
studies, however, have shown that treatment of high-fat diet fed mice [59] and high-fructose diet fed rats [68] with NDGA improves whole body insulin resistance and glucose intolerance. Obviously, more experimental evidence will be needed to sort out the role of PPARα glucose intolerance. Obviously, more experimental evidence will be needed to sort out the role of PPARα in white adipose tissue (WAT); however, it did not significantly impact the expression of genes/proteins involved in fatty acid uptake and oxidation. The lack of effect of NDGA on fatty acid oxidative genes in adipose tissue is likely due to the fact that the fatty acid storage function of adipose tissue-specific PPARγ2 predominates over that of the oxidative function of PPARα [71, 72].

A reduction in hepatic lipogenesis appears to be an alternative mechanism for the lipid-lowering effect of NDGA. While high-fructose feeding increased the expression of sterol regulatory element-binding protein-1c (SREBP-1c) [73, 74] and carbohydrate responsive element-binding protein (ChREBP or Mlxipl) [74, 75], the two transcription factors that primarily regulate hepatic de novo lipogenesis (DNL), NDGA treatment prevented the upregulation of these transcription factors. The nutrition-sensitive SREBP-1c regulates the expression of hepatic lipogenic enzymes (FAS, ACL, ME, S14, SCD1, GPAT1, FADS1, FADS2, ELOVL5, ELOVL6, MTTP, G6PD) and glycolytic enzymes (GCK, PKLR) [73,74] in response to insulin [75, 76], whereas ChREBP regulates some of these genes (L-PK, SREBP-1c, ACL, FAS, ACC, S14, DGAT2, ME, ELOVL2, GLUT4, GCKR) [77, 78] in response to high glucose [76, 79]. NDGA treatment markedly reduced the expression of a large number of SREBP-1c and/or ChREBP target genes including Aty, Fasn, Scd1, Elov2, Elov5, Fads1, Fads2, DGAT2 and Pklr as compared to rats fed a high-fructose diet alone. Surprisingly, NDGA treatment also increased the gene expression of a few genes, such as Elov4, Elov6, and Mogat1. The reason for their upregulation is not clear, but may be related to the fact that these genes, along with several other lipogenic genes, are also regulated by PPARα [64], whose expression, as noted above, is upregulated in response to NDGA treatment. NDGA also increased (Lpl, Vldr) and decreased (Apoa4, Apof) the expression of genes involved in lipid clearance. Again, Lpl and Vldr are known targets of PPARα [64]. Interestingly, expression of hepatic glycolytic genes, Gck and Gckr, was decreased by NDGA treatment; glucokinase (GCK) in liver and pancreatic β-cells is subject to inhibition by glucose regulatory protein (GCKR) [80, 81]. The inhibitory effect of GCKR depends on the presence of fructose-6-phosphate (F6P) and is antagonized.

Table 3 Adipose tissue genes responsive to feeding of a high-fructose diet (HFrD) or HFrD supplemented with NDGA (HFrD-NDGA) (Continued)

| Gene | Description | P-value (HFrD-NDGA) | P-value (HFrD) |
|------|-------------|---------------------|----------------|
| Ppara | Peroxisome proliferator activated receptor alpha (PPAR) | 1.042152 (p = 0.702728) | 1.34318† (p = 0.01657) |
| Ppard | Peroxisome proliferator activated receptor delta (Pparb) | 1.049635 (p = 0.640966) and 1.001442 (p = 0.088966) and 1.023475 (p = 0.858495) | 1.092996 (p = 0.09406) |
| Pparg | Peroxisome proliferator activated receptor gamma | 1.140175 (p = 0.07102) | 0.96347 (p = 0.648174) |
| Ppargc1a | Peroxisome proliferator activated receptor gamma, coactivator 1 alpha (Ppargc1) | 2.166136† (p = 0.013221) | 0.49897 (p = 0.089406) |
| Ppargc1b | Peroxisome proliferator activated receptor, coactivator 1 beta (Pgc1b, Perc) | 0.787663† (p = 0.007863) | 1.092996 (p = 0.0296335) |
| Srebf1 | Sterol regulatory element binding transcription factor 1 (ADD-1, ADD1, SREBP-1, SREBP-1c, Srebp1) | 0.810661† (p = 0.012341) and 0.885992 (p = 0.044261) | 1.17608 (p = 0.063087) and 1.460992† (p = 0.011985) |
| Srebf2 | Sterol regulatory element binding transcription factor 2 (SREBP-2, SREBP2-retired, Srebp2) | 0.854579 (p = 0.062966) | 0.964258 (p = 0.651328) |
| Xbp1 | X-box binding protein 1 (HTF) | 1.168979 (p = 0.878563) | 1.080755 (p = 0.380509) |
by fructose-1-phosphate (F1P) [80, 81]. The NDGA inhibition of Gck is likely to contribute to NDGA-mediated attenuation of lipogenesis, since GCK is the rate-limiting enzyme of glycolysis in the liver, and stimulates glycolysis and lipogenesis by enhancing glucose flux, including production of acetyl-CoA for lipid synthesis [82]. The simultaneous inhibition of expression of both Gck and Gckr in response to NDGA could be explained on the basis of NDGA-mediated inhibition of SREBP-1c and ChREBP; Gck is a known target of SREBP-1c [73, 74], whereas Gckr is regulated by ChREBP [77]. In addition, NDGA-inhibition of Gck may further limit lipogenesis, given that GCK also stimulates glycolysis and lipogenesis at the transcription level via ChREBP [79].

In conclusion, our study shows that chronic dietary treatment with NDGA can attenuate high-fructose diet-induced hypertriglyceridemia and hepatic steatosis (TG accumulation). DNA microarray analysis showed that dietary NDGA profoundly affects the gene expression profiles in liver and skeletal muscle. However, adipose tissue was less dramatically impacted by NDGA treatment. Analysis indicated that NDGA differentially increased the expression of enzymes involved in hepatic fatty acid oxidation and of proteins that facilitate fatty acid transport. The changes were generally greater in liver and skeletal muscle than in adipose tissue. The high-fructose diet containing NDGA also altered the expression of genes related to proteins/enzymes of de novo fatty acid and triglyceride synthesis and lipid clearance. On the basis of the experimental data obtained, the beneficial actions of NDGA on hypertriglyceridemia and steatosis are exerted by a dual mechanism: inhibition of lipogenesis and enhanced functional expression of the key genes for enzymes/proteins involved in fatty acid β-oxidation pathway in liver and skeletal muscle. In adipose tissue, although NDGA inhibits the expression of major enzymes involved in lipogenesis, it also promotes lipid storage by upregulating the expression of TG synthesizing enzymes and attenuating the mRNA levels of proteins that catalyze TG hydrolysis.

Methods

Materials

Oil Red O was obtained from Sigma-Aldrich (St. Louis, MO). Glucose, TG, FFA, and cholesterol measurement kits were obtained from Stanbio Laboratory (Boerne, TX). The rat insulin RIA Kit was obtained from EMD Millipore (Billerica, CA). 60 % Fructose diet (high fructose diet [HFrD] #TD.89247; formula g/Kg: Casein 207; DL-Methionine 3.0; Fructose 600.0; Lard 50.0; Cellulose79.81; Mineral Mix, Rogers-Harper [170760] 50.0; Zinc Carbonate 0.04; Vitamin Mix, Teklad [40060] 10.0 and Green Color 0.15; percent by weight [% kcal from]: Protein 18.3 [20.2]; Carbohydrate 60.4 [66.8]; and Fat 5.2 [13.0]) from Envigo Teklad Diets, Madison, WI. 60 % Fructose diet supplemented with NDGA (2.5 NDGA/kg HFrD) was also custom made by Envigo Teklad Diets. All other reagents used were of analytical grade.

Animals and treatments

All animal experiments were performed according to the procedures approved by the VA Palo Alto Health Care System Animal Care and Use Committee (IACUC). Male Sprague-Dawley (SD) rats, obtained from Harlan Sprague-Dawley (Indianapolis, IN), were used in these studies. For dietary treatment of rats with NDGA, groups of SD rats were fed a standard chow diet for 1 week to acclimatize them to a new environment. Subsequently, one group of rats switched to HFrD supplemented with 2.5 g NDGA/g HFrD and was maintained...
on this diet for 16 weeks. The second group of SD rats was maintained on HFrD alone for 16 weeks, while a third group of rats continued to be fed a chow diet for 16 weeks. Before, during, and at the end of the feeding period, blood samples were taken from the tails of rats for analyses of serum metabolites after 4 h of fast. At the end of the 16-wk treatment period, the rats were fasted, blood was collected, and rats were subsequently euthanized. Blood samples were centrifuged at 4,000 x g for 15 min at 4 °C and the recovered serum samples were stored at -80 °C until analyzed for various metabolites.

Liver, skeletal muscle (mixed gastrocnemius; ~3 % type I fiber, ~6 % type IIA fiber, ~34 % type IID/X fiber and ~57 % type IIB fiber) [90] and white adipose tissue (WAT, epididymal) were excised immediately, weighed, frozen in liquid nitrogen, and stored at -80 °C until analyzed for various metabolites.

**Measurement of serum triglyceride, cholesterol, glucose, free-fatty acids and insulin levels**

Serum glucose, triglyceride, free-fatty acids and total cholesterol levels were determined with commercial assay kits (Stanbio Laboratory, Boerne, TX). Serum insulin levels were quantified using a rat specific insulin RIA Kit (EMD Millipore, Billerica, CA).

**Quantification of hepatic triglyceride content**

Suitable aliquots of liver tissue homogenates were extracted with chloroform-methanol according to the procedure of Folch et al [91], and extracted lipid samples were analyzed for their TG content with an enzymatic procedure of Folch et al [91], and extracted lipid samples were analyzed for their TG content with an enzymatic assay kit as noted above.

**Whole genome microarray**

RNA samples for the whole genome microarray (Rat OneArray v1) were isolated from the liver, white adipose tissue (epididymal) and skeletal muscle (gastrocnemius) using Qiagen RNeasy Plus Mini Kit (Valencia, CA). The RNA analysis, including integrity and quantitation of RNA, was carried out using an Agilent RNA 6000 Nano Kit and an Agilent Bioanalyzer System (Agilent Technologies, Santa Clara, CA). Total RNA was pooled in an equal amount from individual rats of each group and treated with DNase I to remove residual genomic DNA. cDNA synthesis, Cy5-labelling and hybridization to the GeneChip GPL 13694 (rat OneArray v1) were performed by PhalanxBio, Inc. (San Diego, CA). This assay is designed to generate amplified and Cy5 sense-strand DNA targets from the entire expressed genome without bias. Three repeats from each group were performed. The microarray data files have been submitted to the Gene Expression Omnibus; the accession number is GSE81346 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE81346).

**Differential and cluster gene expression analysis**

The raw data from microarrays were analyzed using Partek Genomics Suite software, version 6.3 copyright 2008 (Partek Inc., St. Louis, MO). Briefly, GenePix Results (GPR) files containing the hybridization intensity were imported, followed by quintile normalization and log2 transformation to represent gene expression levels. Liver samples were grouped into: 1) standard chow diet fed (control); 2) high-fructose diet (HFrD)-fed; and 3) HFrD-NDGA fed animals. Three-way ANOVA was performed including diet (chow and HFrD) and NDGA interaction to generate the lists of differentially expressed genes comparing chow, HFrD and HFrD-NDGA. There were three microarrays for each group. For the comparison between chow-fed and HFrD-fed rats, probe sets with a fold change of 2.0 and adjusted P value <0.05 were considered differentially expressed. For the comparison between the HFrD and HFrD-NDGA groups, the analyses were also set with a fold change of 2.0 and adjusted P value of <0.05. The Benjamini-Hochberg false discovery rate (FDR) method was used to select the regulated genes with the lowest FDR. Partek Genomics Suite was used as the first step for quality control of the data on all the samples with two methods: Pearson correlation and Principal Component Analysis (PCA). PCA was performed as a global view of sample clustering, which is related to the total variance in gene expression for all genes. Normalized expression values for all genes were analyzed.

**Pathway analysis**

For each comparison, a list of differentially expressed genes was generated. The gene list, along with associated expression or fold-change values, were further analyzed using Ingenuity Pathway Analysis (Ingenuity Systems, Inc., Redwood City, CA) to identify differentially expressed pathways induced by HFrD feeding or NDGA in HFrD rats. The list of significantly regulated genes, selected by the microarray analysis described above, was loaded in IPA with the following criteria: direct and indirect relationships filtered by species (rat) and by tissue (liver, gastrocnemius or adipose tissue). Then IPA computed the data to generate significant networks of genes that are associated with particular biological functions, diseases and metabolic/signaling pathways.

**Oil Red O staining of liver sections for detection of neutral lipids**

Liver samples were collected from rats, embedded in Tissue Freezing Medium (Leica Microsystems Inc., Buffalo Grove, IL), and stored at -80 °C until used for
sectioning to 8-μM slices. Liver sections were stained with Oil Red O for the visualization of neutral lipids stored in the lipid droplets by using a slight modification of the standard procedure as described earlier from this laboratory (59).

Statistical analysis
All of the data are expressed as the means ± S.E. One way and two-way ANOVA were used to study differences among groups. This was followed by a post hoc comparison using Bonferroni’s multiple-comparison test when necessary. Differences at \( P < 0.05 \) were considered statistically significant. Prism 5 software (GraphPad, La Jolla, CA) was used for all of the statistical calculations.

Abbreviations
FC: Free cholesterol; FFAs: Free fatty acids; HFD: High-fructose rich diet; MetS: Metabolic syndrome; NDGA: Nordihydroguaiaretic acid; NAFLD: Non-alcoholic fatty liver disease; NASH: Nonalcoholic steatohepatitis; TC: Total cholesterol; TG: Triglyceride

Acknowledgements
This work was supported by National Institutes of Health, NHLBI Grant 1R01HL92473, and the Office of Research and Development, Medical Service, Department of Veterans Affairs.

Availability of data and material
The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

Authors’ contributions
Conceived and designed the experiments: HZ, WJS, FBK, SA. Performed the experiments: HZ, YL, YFC, JT. Analyzed the data: HZ, AB, SB, WJS. Prepared the manuscript: HZ, AB, SB, WJS. Wrote the manuscript: WJS, FBK, SA. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Author details
1 Geriatric Research, Education and Clinical Center, VA Palo Alto Health Care System, Palo Alto, CA, USA. 2Division of Endocrinology, Stanford University, Stanford, CA, USA. 3Present Address: Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. 4Present Address: Department of Pediatrics, Saint Louis University School of Medicine, St. Louis, MO, USA.

Received: 28 May 2016 Accepted: 14 September 2016
Published online: 29 September 2016

References
1. Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old question and new insights. Science. 2011;332(6037):1519–23.
2. Vernon G, Baranova A, Younossi ZM. Systematic Review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274–85.
3. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of nonalcoholic fatty liver disease (NAFLD) and diagnostic accuracy of noninvasive tests for liver disease severity. Ann Med. 2011;43:617–49.
4. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):586–90.
5. Kawano Y, Cohen DE. Mechanism of hepatic triglyceride accumulation in nonalcoholic liver disease. J Gastroenterol. 2013;48(4):434–41.
6. Smith BW, Adams LA. Nonalcoholic fatty liver disease. Curr Rev Clin Lab Sci. 2011;48(3):97–113.
7. Wang DQ-H, Portincasa P, Neuschwander-Tetri BA. Steatosis in the liver. Comp Physiol. 2013;3:1409–532.
8. Farrell GC, Larner CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99–S112.
9. Tinakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: Pathology and pathogenesis. Ann Rev Pathol Mech Dis. 2010;5:145–71.
10. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656–65.
11. Alameda-Valdes P, Cuevas-Ramos D, Aguilar-Salinas CA. Metabolic syndrome and nonalcoholic fatty liver disease. Ann Hepatol. 2009;8 Suppl 1:18–24.
12. Ansee MQ, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.
13. Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637–53.
14. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fuji K, Omatsu T, Nakajima T, Saru H, Shimazaki M, Kato T, Okuda J, Ito K. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med. 2005;143(10):722–8.
15. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Maini R, Natale S, Vanni E, Villanova N, Melchionda N, Rizzetto M. Nonalcoholic fatty liver steatohepatitis, and metabolic syndrome. Hepatology. 2003;37(4):917–23.
16. Rector RS, Thyfault JP, Wei Y, Idkaj JA. Nonalcoholic fatty liver disease and metabolic syndrome. World J Gastroenterol. 2008;14(2):185–92.
17. Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011;7(8):456–65.
18. Williams KH, Shackle NA, Correll MD, McLennan SW, Twigg SM. Diabetes and nonalcoholic fatty liver disease: a pathogenic duo. Endoc Rev. 2013;34(1):84–129.
19. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato SM, Frucht-J-C, James PT, Loria CM, Smith Jr SC. Harmonizing the metabolic syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5
20. Grundy SM. Metabolic syndrome pandemic. Anterioscler Thromb Vasc Biol. 2008;28:629–36.
21. O’Neill S, O’Driscoll L. Metabolic syndrome. a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015;16:1–12.
22. Bhatia LS, Curpen N, Byrne CD. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol. 2012;27(4):420–8.
23. Fargion S, Pozio M, Fiaccanzi AL. Nonalcoholic fatty liver disease and vascular disease: State-of-the-art. World J Gastroenterol. 2014;20(37):13306–24.
24. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50.
25. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charbon T, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the study of liver diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.
26. Ratziu V. Pharmacological agents for NASH. Nat Rev Gastroenterol Hepatol. 2013;10(11):676–85.
27. Soutiranayanan AC, Pagadala MR, Kirwan JP. Management of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2013;59(1):69–87.
28. Lim JS, Mietus-Snyder M, Vakente A, Schwarz JAM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7:251–64.
29. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol. 2013;9:13–27.
30. Neuschwander-Tetri BA. Carbohydrate intake and nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2013;16:446–52.
31. Rector RS, Thyfault JP. Does physical inactivity cause nonalcoholic fatty liver disease? J Appl Physiol. 2011;111:1828–35.
32. Vos MB, Lavine JE. Dietary fructose in nonalcoholic fatty liver disease. Hepatology. 2013;57:2525–31.
33. Yasutake K, Kohjima M, Kotok H, Nakashima M, Nakamura M, Enjoji M. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:1756–67.

34. Bray GA, Popkin BM. Calorie-sweetened beverages and fructose: what we have learned 10 years later. Pediatr Obes. 2013;8:242–8.

35. Lustig RH. Fructose: It’s “alcohol without the buzz.” Adv Nutr. 2013;4:226–35.

36. Marriott BP, Cole N, Lee E. National estimates of dietary fructose increased from 1977 to 2004 in the United States. J Nutr. 2009;139:1228S–35.

37. Park YK, Yetley EA. Intakes and food sources of fructose in the United States. Am J Clin Nutr. 1993;58:735–47.

38. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem. 2012;23:205–8.

39. Aebertl I, Hochuli M, Gerber PA, Sae L, Murer SB, Tappy L, Spinaz GA, Bernes K. Moderate amounts of fructose consumption impairs insulin sensitivity in healthy young men. Diabetes Care. 2013;36:150–6.

40. Lé KA, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in subjects with healthy weight and without a family history of type 2 diabetes. Am J Clin Nutr. 2009;89:1760–5.

41. Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in nonalcoholic fatty liver disease. Nutrition. 2009;25:1322–34.

42. Welsh JA, Sharma A, Abramson JL, Vaccarino V, Gillespie C, Vos MB. Caloric sweetened beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009;119:1322–34.

43. Stanhope KL, Schwarz JM, Keim NL, Sc G, Bremer AA, Graham JL, Hatcher B, Schaefer EJ, Ith M, Kreis R, Faeh D, Bortolotti M, Tran C, Boesch C, Tappy L. Dietary habits and behaviors associated with nonalcoholic fatty liver disease. J Clin Invest. 2002;119:1322–34.

44. Arteaga S, Andrade-Cetto A, Cárdenas R. Sensitivity of the Scap/SREBP-pathway is essential for developing diabetic fatty liver and carbohydrate-induced hepatic steatosis. PLoS ONE. 2015;10(9):e0138203.

45. Nakamura MT, Yudell BE, Loor JJ. Regulation of energy metabolism by long-chain fatty acids. Prog Lipid Res. 2014;53:124–33.

46. Finck BN, Bernal-Mizrachi C, Han DH, Coleman T, Sambandham N, LaRiviere LL, Holloszy JO, Semenkovich CF, Kelly DP. A potential link between muscle peroxisome proliferator-activated receptor-α signaling and obesity-related diabetes. Cell Metab. 2005;1:133–44.

47. Sample BK, Chatterjee WK, O’Rahilly S. PPARα and human metabolic disease. J Clin Invest. 2006;116:581–9.

48. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARy. Annu Rev Biochem. 2008;77:289–312.

49. Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka K, Osuga J, Harada K, Gotoda T, Sato T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Sato R, Kinura S, Ishibashi S, Yamada N. Transcriptional activities of nuclear SREBP-1α, -1c, and -2 to different target promoters of lipogenic and cholesterologenic genes. J Lipid Res. 2002;43:1220–5.

50. Knebel B, Haas J, Harwig S, Jacob S, Köllmer C, Nitzgen U, Muller-Wieland D, Muller M, Kersten S. Peroxisome proliferator-activated receptor γ mediates hypolipidemia, inflammation and cancer. Nucl Recept Signal. 2010;8:e002.

51. Jeong Y-S, Kim D, Lee YS, Jang H-Y, Cho Y-H, Kim WM, Osborne TF, Horton JD, Jun H-S, Ahn Y-H, Cha J-Y. Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. PLoS ONE. 2011;6:e22544.
79. Uyeda K, Repa JJ. Carbohydrate response element binding protein, ChREBP, a transcription factor coupling glucose utilization and lipid synthesis. Cell Metab. 2006;4:107–10.

80. Anderka O, Boyken J, Aschenbach U, Batzer A, Boscheinen O, Schmoll D. Biophysical characterization of the interaction between hepatic glucokinase and its regulatory protein: impact of physiological and pharmacological effectors. J Biol Chem. 2008;283:31333–40.

81. Zelent B, Raimondo A, Barrett A, Buettger CW, Chen P, Gloyn AL, Matschinsky FM. Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence. Biochem J. 2014;459:551–64.

82. Foufelle E, Ferré P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J. 2002;366:377–91.

83. An J, Muoio DM, Shiota M, Fujimoto Y, Cline GW, Shulman GI, Koves TR, Stevens R, Millington D, Newgard CB. Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance. Nat Med. 2004;10:268–74.

84. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem. 1997;151:1–14.

85. Kerner J, Hoppel C. Fatty acid import into mitochondria. Biochim Biophys Acta. 2000;1486:1–17.

86. Campbell FM, Kozak R, Wagner A, Altarejos JY, Dyck JB, Belke DD, Severson DL, Kelly DP, Lopaschuk GD. A role for peroxisome proliferator-activated receptor α (PPARα) in the control of cardiac malonyl-CoA levels: Reduced fatty acid oxidation rates and increased oxidation rates in the hearts of mice lacking PPARαs are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem. 2002;277:4096–103.

87. Lee GY, Kim NH, Zhao ZS, Cha BS, Kim YS. Peroxisomal-proliferator receptor α activated transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level. Biochem J. 2004;378:983–90.

88. Saha AK, Schwarsin AJ, Rodunit R, Massé F, Kaushik V, Tomhein K, Prentki M, Ruderman NB. Activation of malonyl-CoA decarboxylase in rat skeletal muscle by contraction and the AMP-activated protein kinase activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside. J Biol Chem. 2000;275:24279–83.

89. Park H, Kaushik VK, Constant S, Prentki M, Przybytkowski E, Ruderman NB, Saha AK. Coordinate regulation of malonyl-CoA decarboxylase, sn-glycero-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in response to exercise. J Biol Chem. 2002;277:32571–7.

90. Delp MD, Duan C. Composition and size of type I, IIa, IIb, and IIB fibers and citrate synthase activity of rat muscle. J Appl Physiol. 1996;80:261–70.

91. Folch J, Lees M, Sloan-Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem. 1957;226:497–509.